E7F0 Stock Overview
Engages in the development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cizzle Biotechnology Holdings Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.018 |
| 52 Week High | UK£0.03 |
| 52 Week Low | UK£0.017 |
| Beta | 0.38 |
| 1 Month Change | 0% |
| 3 Month Change | -22.92% |
| 1 Year Change | -26.00% |
| 3 Year Change | -70.63% |
| 5 Year Change | n/a |
| Change since IPO | -71.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| E7F0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.8% | -1.6% | -0.5% |
| 1Y | -26.0% | -24.7% | 5.2% |
Return vs Industry: E7F0 underperformed the German Biotechs industry which returned -24.7% over the past year.
Return vs Market: E7F0 underperformed the German Market which returned 5.2% over the past year.
Price Volatility
| E7F0 volatility | |
|---|---|
| E7F0 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: E7F0's share price has been volatile over the past 3 months.
Volatility Over Time: E7F0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | n/a | www.cizzlebiotechnology.com |
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, engages in the development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer in the United Kingdom. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Cizzle Biotechnology Holdings Plc Fundamentals Summary
| E7F0 fundamental statistics | |
|---|---|
| Market cap | €7.91m |
| Earnings (TTM) | -€2.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs E7F0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E7F0 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£1.72m |
| Earnings | -UK£1.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0043 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did E7F0 perform over the long term?
See historical performance and comparison